M. Baehner

Phase I clinical study of RG7356, an anti-CD44 humanized antibody, in patients with acute myeloid leukemia

P. Paschka, G. Martinelli, W. Fiedler, 2016, Oncotarget.

Novel CCR5 monoclonal antibodies with potent and broad-spectrum anti-HIV activities.

Jun Zhang, M. Dioszegi, S. Sankuratri, 2007, Antiviral research.

PK/PD Mediated Dose Optimization of Emactuzumab, a CSF1R Inhibitor, in Patients With Advanced Solid Tumors and Diffuse‐Type Tenosynovial Giant Cell Tumor

G. Meneses‐Lorente, C. Ries, A. Walz, 2020, Clinical pharmacology and therapeutics.

Phase I study of RG7155, a novel anti-CSF1R antibody, in patients with advanced/metastatic solid tumors.

J. Blay, M. Toulmonde, A. Italiano, 2015 .

CSF1R inhibition with emactuzumab in locally advanced diffuse-type tenosynovial giant cell tumours of the soft tissue: a dose-escalation and dose-expansion phase 1 study.

J. Blay, M. Toulmonde, A. Italiano, 2015, The Lancet. Oncology.

Crystal Structure of Human TWEAK in Complex with the Fab Fragment of a Neutralizing Antibody Reveals Insights into Receptor Binding

J. Niewoehner, K. Hopfner, K. Lammens, 2013, PloS one.

Anti-tumoral, anti-angiogenic and anti-metastatic efficacy of a tetravalent bispecific antibody (TAvi6) targeting VEGF-A and angiopoietin-2

C. Klein, Markus Thomas, U. Brinkmann, 2016, mAbs.